Australia's most trusted
source of pharma news
Posted 28 April 2026 AM
The PBAC has given the thumbs up to a submission by the Department of Health to move AbbVie's Humira and various brands of infliximab, the active ingredient in J&J's Remicade, to the first line for paediatric patients with severe, and moderate to severe Crohn disease respectively. The prior therapy requirements for paediatric patients with Crohn's disease and ulcerative colitis remain.
This comes after lobbying from patient groups, including repeated questioning of the Department by Independent Senator for the ACT, David Pocock, during Senate Estimates. While the cost of Humira and infliximab are higher than standard medicines, the PBAC advised that the proposed first-line treatment would be cost effective at the current price.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.